Insider Spends US$387k Buying More Shares In Relmada Therapeutics
Insider Spends US$387k Buying More Shares In Relmada Therapeutics
Potential Relmada Therapeutics, Inc. (NASDAQ:RLMD) shareholders may wish to note that the CEO & Director, Sergio Traversa, recently bought US$387k worth of stock, paying US$3.87 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 69%, potentially signalling some real optimism.
潛在的Relmada Therapeutics, Inc.(納斯達克股票代碼:RLMD)股東不妨注意,首席執行官兼董事塞爾吉奧·特拉弗爾薩最近購買了價值38.7萬美元的股票,每股支付了3.87美元。這無疑使我們對最好的情況充滿期待,尤其是因爲他們因此將自己的持股量增加了69%,這可能預示着一些真正的樂觀情緒。
The Last 12 Months Of Insider Transactions At Relmada Therapeutics
Relmada Therapeutics 過去 12 個月的內幕交易
Notably, that recent purchase by Sergio Traversa is the biggest insider purchase of Relmada Therapeutics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of US$3.93. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
值得注意的是,塞爾吉奧·特拉弗爾薩最近的收購是我們去年對Relmada Therapeutics股票的最大一次內幕收購。這意味着內部人士樂於以高於當前3.93美元的價格購買股票。從那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士爲股票支付的價格非常重要。總的來說,當內部人士以高於當前的價格購買股票時,它會引起我們的注意,因爲這表明他們認爲即使價格更高,也值得買入。
While Relmada Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
儘管Relmada Therapeutics內部人士在去年購買了股票,但他們沒有賣出。下圖顯示了去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240201/0-4d56e571872edaa59b9caf8ec1afd12d-0-72449a9cde60d7866e8c624f79f3a62a.png/big)
Relmada Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Relmada Therapeutics並不是內部人士唯一買入的股票。對於那些喜歡尋找獲利投資的人來說,這份最近有內幕收購的成長型公司的免費清單可能就是入場券。
Insider Ownership
內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 8.6% of Relmada Therapeutics shares, worth about US$10m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我們通常希望看到相當高的內部所有權水平。業內人士擁有Relmada Therapeutics8.6%的股份,價值約1000萬美元。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。
So What Do The Relmada Therapeutics Insider Transactions Indicate?
那麼,Relmada Therapeutics的內幕交易表明了什麼呢?
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Relmada Therapeutics we think they are probably pretty confident of a bright future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example, Relmada Therapeutics has 3 warning signs (and 1 which is concerning) we think you should know about.
很高興看到最近的購買。長期的內幕交易也給了我們信心。但是,我們對公司虧損的事實有不同的看法。鑑於內部人士還擁有Relmada Therapeutics的相當一部分股份,我們認爲他們可能對光明的未來充滿信心。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。例如,Relmada Therapeutics有3個警告信號(其中一個令人擔憂),我們認爲你應該知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。